查詢結果分析
來源資料
相關文獻
- Tramadol/Acetaminophen Fixed-Dose Combination (Ultracet) is as Effective as Fentanyl Transdermal System for Gynecologic Cancer Pain
- The Significance of Pain Among Chinese Patients with Cancer in Hong Kong
- 疼痛的心身醫學觀:從疾病為中心到病人為中心
- 疼痛對癌症病患焦慮與憂鬱之影響
- 治療癌症疼痛的倫理考量
- 癌症疼痛因應量表之發展與癌症疼痛因應行為之探討
- 癌症疼痛之處置
- 臨床使用嗎啡控制癌末疼痛之研究
- 病人對癌痛及麻醉性止痛藥之信念探討--量表發展與現況
- 大學護生對癌症疼痛及麻醉性止痛藥之信念與知識及其相關因素探討
頁籤選單縮合
題 名 | Tramadol/Acetaminophen Fixed-Dose Combination (Ultracet) is as Effective as Fentanyl Transdermal System for Gynecologic Cancer Pain=Tramadol Hydrochloride/Acetaminophen固定劑型應用在婦科癌症病人癌症疼痛的緩解和經皮膚吸收的Fantanyl一樣有效 |
---|---|
作 者 | 孫孝倫; 何志明; | 書刊名 | 疼痛醫學雜誌 |
卷 期 | 24:1 2014.03[民103.03] |
頁 次 | 頁1-6 |
分類號 | 416.5 |
關鍵詞 | 癌症疼痛; 婦科癌症病人; Ultracet; Fentanyl; Cancer pain; Gynecologic cancer patients; |
語 文 | 英文(English) |
中文摘要 | 復發性婦科癌症病人,疼痛是一常見徵狀且需要進一步評估和處理。臨床上使用經皮膚吸收的Fantanyl貼片已成功的緩解癌症引起的疼痛。Tramadol hydrochloride 75毫克和acetaminophen 325毫克組合(Ultracet)可提供快速和有效的止痛效果。本研究的目的是在比較Ultracet應用在婦科癌症病人癌症疼痛的緩解和經皮膚吸收的Fantanyl是否一樣有效。本研究屬回溯行研究,共收集40位中度至重度((在10公分visual analog score量表中≧4公分)癌症疼痛無法使用NSAIDs或cyc1ooxygenase-2選擇性抑制劑達到緩解的復發性婦科癌症病人。他們之中有12位接受Ultracet,28位接受經皮膚吸收的Fantanyl貼片。藥物有效性最終判定是根據多少比率的病人達到疼痛強度改善的比例從基準線到最後評估超過百分之三十。結果發現治療前和治療後兩組病人疼痛強度改善比例超過百分之三十的比率是相似的((83%vs89%, P>0.05)。我們得到結論Ultracet固定劑型應用在婦科癌症病人癌症疼痛的緩解和經皮膚吸收的Fantanyl一樣有效。 |
英文摘要 | Objective: In recurrent gynecologic cancer patients, pain is a common condition need to be assessed and managed. Fentanyl transdermal patch has been used successfully to relieve cancer pain. The combination of tramadol hydrochloride 75mg and acetaminophen 325mg (Ultracet) has been shown to provide rapid and effective analgesic effects. The goal of this study was to compare the efficacy of Ultracet and fentanyl transdermal patch for the treatment of cancer pain in recurrent gynecologic cancer patients. Methods: A retrospective study conducted in Cathay General Hospital enrolled 40 recurrent gynecologic cancer patients with moderate to severe (≧4 cm on a 10 cm visual analog score) cancer pain insufficiently relieved by previous NSAIDs or cyclooxygenase-Z-selective inhibitors. They either received Ultracet (n=12) or fentanyl transdermal patch (n=28). The efficacy endpoint was the percentage of patients with a pain intensity change rate ≧30% from baseline to final evaluation. Results: The percentage of patients with a pain intensity change rate (≧30%) before and after treatment was similar in both Ultracet group and fentanyl transdermal patch group (83% vs 89%, P> 0.05). Conclusion: Ultracet is as effective as fentanyl transdermal patch for the treatment of cancer pain in gynecologic cancer patients. |
本系統中英文摘要資訊取自各篇刊載內容。